Before any drug reaches the market, its name is thoroughly examined to identify misleading or potentially confusing names. FDA Drug Info Rounds pharmacists discuss FDA's responsibility for reviewing and approving new product names. The screening process for proposed proprietary drug names is reviewed, and the role of the Division of Medication Error Prevention and Analysis (DMEPA) and Office of Prescription Drug Promotion (OPDP) are explained.
Facebook Comments